コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 d not observe JC viremia, JC nephropathy, or progressive multifocal leukoencephalopathy.
2 the central nervous system, where it causes progressive multifocal leukoencephalopathy.
3 sks of these therapies, such as the risk for progressive multifocal leukoencephalopathy.
4 iformly fatal demyelinating disease known as progressive multifocal leukoencephalopathy.
5 ortunately been implicated in three cases of progressive multifocal leukoencephalopathy.
6 he risk of serious adverse events, including progressive multifocal leukoencephalopathy.
7 tral nervous system (CNS) in humans known as progressive multifocal leukoencephalopathy.
8 nists may thus be useful in the treatment of progressive multifocal leukoencephalopathy.
9 may lead to new forms of immunotherapies for progressive multifocal leukoencephalopathy.
10 s with the JCV-induced demyelinating disease progressive multifocal leukoencephalopathy.
11 central nervous system demyelinating disease progressive multifocal leukoencephalopathy.
12 ubacute, debilitating demyelinating disease, progressive multifocal leukoencephalopathy.
13 ed immunity is most commonly associated with progressive multifocal leukoencephalopathy.
14 One patient died of progressive multifocal leukoencephalopathy.
15 There were no cases of progressive multifocal leukoencephalopathy.
16 sclerosis, but is associated with a risk of progressive multifocal leukoencephalopathy.
17 as an infusion for adoptive immunotherapy of progressive multifocal leukoencephalopathy.
18 anticipated life threatening adverse effect: progressive multifocal leukoencephalopathy.
19 Fifty-three patients (0.9%) had confirmed progressive multifocal leukoencephalopathy.
20 y progressing demyelinating disease known as progressive multifocal leukoencephalopathy.
21 ith multiple sclerosis, those susceptible to progressive multifocal leukoencephalopathy.
22 talizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy.
23 the brain, causing a demyelinating disease, progressive multifocal leukoencephalopathy.
24 susceptible to lytic infection, resulting in progressive multifocal leukoencephalopathy.
25 s not changed in the brains of patients with progressive multifocal leukoencephalopathy.
26 been limited by its association with risk of progressive multifocal leukoencephalopathy.
27 the mechanism of natalizumab treatment with progressive multifocal leukoencephalopathy.
28 tibility-weighted sequences in patients with progressive multifocal leukoencephalopathy.
29 tment of other cases of immunodeficiency and progressive multifocal leukoencephalopathy.
30 nce imaging-detected lesions consistent with progressive multifocal leukoencephalopathy.
31 ions of elevated perfusion within lesions of progressive multifocal leukoencephalopathy.
32 e herpesvirus infections and potentially for progressive multifocal leukoencephalopathy.
33 alizumab recipients were diagnosed as having progressive multifocal leukoencephalopathy.
34 /isosporiasis, 90% and infinite (1.61/0.00); progressive multifocal leukoencephalopathy, 87% and 19 (
35 ividuals, the virus can reactivate and cause progressive multifocal leukoencephalopathy, a deadly dis
36 lyomavirus, JCPyV, is the causative agent of progressive multifocal leukoencephalopathy, a rare demye
39 18 years or older) with clinically definite progressive multifocal leukoencephalopathy and disease p
41 yomavirus JC (JCV) is the causative agent of progressive multifocal leukoencephalopathy and of JCV gr
42 the ofatumumab group (the most common being progressive multifocal leukoencephalopathy and pneumonia
43 ho sequences in relation to the diagnosis of progressive multifocal leukoencephalopathy and to review
44 e clinical and pathological presentations of progressive multifocal leukoencephalopathy, and advances
45 Hodgkin lymphoma, M. tuberculosis infection, progressive multifocal leukoencephalopathy, and cryptosp
46 y have shed new light on the pathogenesis of progressive multifocal leukoencephalopathy, and on its p
47 al leukoencephalopathy, our understanding of progressive multifocal leukoencephalopathy, and the mech
49 a patient treated with natalizumab died from progressive multifocal leukoencephalopathy, associated w
50 ous events were notified except 1 death from progressive multifocal leukoencephalopathy at month 4.
51 phages and activated microglia in stroke and progressive multifocal leukoencephalopathy, but not expr
52 ures and patients can be risk stratified for progressive multifocal leukoencephalopathy by testing fo
55 central nervous system disease analogous to progressive multifocal leukoencephalopathy caused by Joh
56 otential to serve as a valuable biomarker of progressive multifocal leukoencephalopathy disease and t
57 lizumab discontinuation, 1 patient developed progressive multifocal leukoencephalopathy during the ob
60 nating syndromes (including cases resembling progressive multifocal leukoencephalopathy) have been re
61 ion of Purkinje cells and absence of classic progressive multifocal leukoencephalopathy histopatholog
62 95% confidence interval [CI], 2.98-8.87) and progressive multifocal leukoencephalopathy (HR, 4.22; 95
63 al nervous system of a 59-year-old male with progressive multifocal leukoencephalopathy immune recons
64 CV) causes the central demyelinating disease progressive multifocal leukoencephalopathy in about 5% o
65 therapy has changed the clinical spectrum of progressive multifocal leukoencephalopathy in HIV-infect
66 ive agent of the rare demyelinating disease, progressive multifocal leukoencephalopathy in immunocomp
67 JCV, causes the fatal demyelinating disease progressive multifocal leukoencephalopathy in immunocomp
68 gic agent of the fatal demyelinating disease progressive multifocal leukoencephalopathy in immunocomp
70 CV) may lead to development of demyelinating progressive multifocal leukoencephalopathy in patients w
71 to determine what led to the development of progressive multifocal leukoencephalopathy in the natali
80 nts should be considered only if the risk of progressive multifocal leukoencephalopathy is high and o
82 ype virus first isolated from a patient with progressive multifocal leukoencephalopathy, is character
84 sought to characterize perfusion patterns of progressive multifocal leukoencephalopathy lesions by ar
85 nse hyperperfusion within and at the edge of progressive multifocal leukoencephalopathy lesions in a
87 42 MS lesions, 12 acute ischemic lesions, 8 progressive multifocal leukoencephalopathy lesions, and
88 is a lytic infection of oligodendrocytes in progressive multifocal leukoencephalopathy; less common
90 in transplant patients causing nephropathy, progressive multifocal leukoencephalopathy, Merkel cell
91 logies with prominent myelin injury, namely, progressive multifocal leukoencephalopathy, metachromati
92 , these data suggest that JCV propagation in progressive multifocal leukoencephalopathy might be acce
93 he investigation of candidate biomarkers for progressive multifocal leukoencephalopathy might inform
100 s, the three cases of natalizumab-associated progressive multifocal leukoencephalopathy, our understa
101 and the evolution of JC polyomavirus-induced progressive multifocal leukoencephalopathy over three di
103 ncipal target of JCV productive infection in progressive multifocal leukoencephalopathy patients, lit
104 e been associated with prolonged survival in progressive multifocal leukoencephalopathy patients.
105 psing-remitting multiple sclerosis died from progressive multifocal leukoencephalopathy (PML) after h
106 nd 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after r
107 ed with a favorable outcome in patients with progressive multifocal leukoencephalopathy (PML) and cro
108 course of patients with natalizumab-related progressive multifocal leukoencephalopathy (PML) and ful
109 frequently fatal demyelinating brain disease progressive multifocal leukoencephalopathy (PML) carry s
111 to investigate whether NfL are biomarkers of progressive multifocal leukoencephalopathy (PML) during
112 patients with multiple sclerosis who develop progressive multifocal leukoencephalopathy (PML) followi
114 e of the central nervous system (CNS) called Progressive Multifocal Leukoencephalopathy (PML) in immu
115 ive agent of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in immu
116 s the aggressive brain-demyelinating disease progressive multifocal leukoencephalopathy (PML) in indi
117 (Tysabri) was associated with a few cases of progressive multifocal leukoencephalopathy (PML) in mult
118 iomarkers associated with the development of progressive multifocal leukoencephalopathy (PML) in mult
120 des the laboratory confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in pati
121 velopment of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in pati
123 us (JCV) seropositivity is a risk factor for progressive multifocal leukoencephalopathy (PML) in pati
124 nd can cause the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML) in the
161 itors of this process.IMPORTANCE The disease progressive multifocal leukoencephalopathy (PML) is caus
162 ry syndrome (IRIS) in natalizumab-associated progressive multifocal leukoencephalopathy (PML) is of c
164 a result of immunocompromise and manifest as progressive multifocal leukoencephalopathy (PML) or gran
165 asma, and cerebrospinal fluid [CSF]) from 19 progressive multifocal leukoencephalopathy (PML) patient
166 n latent JC polyomavirus (JCV) infection and progressive multifocal leukoencephalopathy (PML) remains
167 ic agent of the human demyelinating disease, progressive multifocal leukoencephalopathy (PML) seen in
169 rstitial nephritis in primary infections and progressive multifocal leukoencephalopathy (PML) upon re
170 magnetic resonance imaging of the brain, and progressive multifocal leukoencephalopathy (PML) was ult
175 ppressed patients, JCV infection can lead to progressive multifocal leukoencephalopathy (PML), a fata
176 n the central nervous system (CNS) and cause progressive multifocal leukoencephalopathy (PML), a fata
178 perience JCPyV reactivation, which can cause progressive multifocal leukoencephalopathy (PML), a neur
180 nsplant recipients are at risk of developing progressive multifocal leukoencephalopathy (PML), a rare
181 mmune system is compromised, JCPyV can cause progressive multifocal leukoencephalopathy (PML), a rare
182 atabases, Goldman and colleagues report that progressive multifocal leukoencephalopathy (PML), a vira
183 olyomavirus JC (JCV), the etiologic agent of progressive multifocal leukoencephalopathy (PML), an acq
184 avirus, a member of the human virome, causes progressive multifocal leukoencephalopathy (PML), an oft
186 of a patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML), an opp
187 Major concerns regard the risk of developing progressive multifocal leukoencephalopathy (PML), and th
188 nts of serious diseases in humans, including progressive multifocal leukoencephalopathy (PML), BK vir
191 ent of the fatal human demyelinating disease progressive multifocal leukoencephalopathy (PML), is an
192 s) known to be associated with CD treatment (progressive multifocal leukoencephalopathy (PML), seriou
193 actors affecting survival after diagnosis of progressive multifocal leukoencephalopathy (PML), we ana
194 stently found in the brains of patients with progressive multifocal leukoencephalopathy (PML), wherea
195 ive agent of the fatal demyelinating disease progressive multifocal leukoencephalopathy (PML), which
223 tumors [lymphomas and gliomas] and two with progressive multifocal leukoencephalopathy [PML]) with t
224 lesion fraction was significantly greater in progressive multifocal leukoencephalopathy progressors t
225 sequences seems to support the diagnosis of progressive multifocal leukoencephalopathy, regardless o
227 ide, both of which induce degradation of the progressive multifocal leukoencephalopathy/retinoic acid
228 ded-interval dosing is associated with lower progressive multifocal leukoencephalopathy risk, but the
230 r SV40 distribution in classic demyelinating progressive multifocal leukoencephalopathy, some of the
232 not powered to assess differences in risk of progressive multifocal leukoencephalopathy, the occurren
235 cts of Tecfidera and its rare side effect of progressive multifocal leukoencephalopathy, we conducted
236 y virus (HIV) infection and biopsy-confirmed progressive multifocal leukoencephalopathy were randomly
237 opathy; lymphoma, hepatic encephalopathy and progressive multifocal leukoencephalopathy were seen mor
238 virus JC virus (JCV) is a causative agent of progressive multifocal leukoencephalopathy which results
239 ic agent of the fatal demyelinating disease, progressive multifocal leukoencephalopathy, which usuall
240 the prognosis of HIV-infected patients with progressive multifocal leukoencephalopathy who are treat
241 No reliable treatment options are known for progressive multifocal leukoencephalopathy with underlyi
242 ter the first infusion, whereas five died of progressive multifocal leukoencephalopathy within 3 mont
244 virus-specific T cells for immunotherapy in progressive multifocal leukoencephalopathy would be feas